PROPYLTHIOURACIL CAS No. 51-52-5

First Listed in the Fourth Annual Report on Carcinogens

CARCINOGENICITY

Propylthiouracil is *reasonably anticipated to be a human carcinogen* based on sufficient evidence for carcinogenicity in experimental animals (IARC 1974, 1982, 1987, 2001). When administered in the diet, propylthiouracil induced chromophobe adenomas of the anterior pituitary and carcinomas of the thyroid in mice and solid and cystic type adenomas of the thyroid in female rats. Propylthiouracil administered in the drinking water induced increased incidences of thyroid carcinomas and adenomas in rats of both sexes, malignant thyroid lesions, with some metastases, in hamsters of both sexes, and thyroid adenomas in male guinea pigs. Simultaneous administration of propylthiouracil and dried thyroid powder induced single or multiple chromophobe adenomas of the pituitary and carcinomas and adenomas of the thyroid in rats of both sexes. Administration of propylthiouracil and potassium iodide in the drinking water increased the incidence of thyroid adenomas and induced one carcinoma in rats. In a short-term study, oral administration of propylthiouracil induced hyperplasia of the thyroid in dogs (IARC 1974, 1982).

No adequate data were available from human studies to evaluate the carcinogenicity of propylthiouracil in humans (IARC 1974, 1982, 1987, 2001). In a survey of 331 hyperthyroid patients treated with antithyroid drugs and later with thyroidectomy, four malignant thyroid lesions were detected in patients diagnosed with Grave's disease; for these patients, drug therapy had continued for at least one year. There has also been a single case report of acute myeloblastic leukemia in a woman following propylthiouracil treatment (Aksoy *et al.* 1974, IARC 1982). Two case-control studies of thyroid cancer did not show a significant association with treatment with anti-thyroid medications (IARC 2001).

PROPERTIES

Propylthiouracil occurs as a white, crystalline powder with a starch-like appearance and a bitter taste. It is sensitive to light and prolonged exposure to air. It is slightly soluble in water at 20°C, soluble in boiling water, ethanol, acetone, and aqueous solutions of ammonia and alkali hydroxides and practically insoluble in ether, chloroform, and benzene. It is incompatible with strong oxidizers, strong acids, and strong bases, and forms complexes with divalent metals (IARC 1974, HSDB 2001, NTP 2001).

USE

Propylthiouracil is commercially available in the United States as a USP grade containing 98 to 100.5% active ingredient on a dried basis, with small amounts of thiourea present as an impurity. Propylthiouracil has been used since the 1940s as an antithyroid agent for the treatment of hyperthyroidism. Veterinary applications of propylthiouracil reportedly included its use as a metabolic depressant to promote fattening in animals, but this use has been banned (IARC 1974, 2001).

PRODUCTION

Current production data for propylthiouracil are not available. Chem Sources (2001) identified 10 U.S. suppliers of the compound. The 1979 TSCA Inventory identified one producer of propylthiouracil producing 500 lb in 1977 and one importer with no reported import volume (TSCA 1979). No current data on import or exports of propylthiouracil were available.

EXPOSURE

The primary route of potential human exposure to propylthiouracil is ingestion of the compound as a drug. Potential occupational exposure to propylthiouracil may occur during the production, formulation, packaging, or administration of pharmaceuticals. The National Occupational Hazard Survey, conducted by NIOSH from 1972 to 1974, estimated that 297 workers were potentially exposed to propylthiouracil in the workplace (NIOSH 1976). The National Occupational Exposure Survey (1981-1983) indicated that 1,775 workers, including 817 women, potentially were exposed to propylthiouracil. This estimate was derived from observations of the use of the actual compound (89% of total observations) and trade name products (11%) (NIOSH 1984, HSDB 2001).

REGULATIONS

EPA requires handling and reporting and record-keeping for propylthiouracil under the Resource Conservation and Recovery Act (RCRA).

FDA regulates the use of propylthiouracil as a pharmaceutical to treat hyperthyroidism under the Food, Drug, and Cosmetic Act (FD&CA).

OSHA regulates propylthiouracil under the Hazard Communication Standard and as a chemical hazard in laboratories. Regulations are summarized in Volume II, Table 156.

REFERENCES

Aksoy, M., S. Erdem, H. Tezel, and T. Tezel. Acute Myeloblastic Leukemia after Propylthiouracil. Lancet Vol. 1, 1974, pp. 928-929.

Chem Sources. Chemical Sources International, Inc. http://www.chemsources.com, 2001.

HSDB. Hazardous Substances Data Bank. Online database produced by the National Library of Medicine. Propyl Thiouracil. Profile last updated May 16, 2001. Last review date, September 14, 1995.

IARC. International Agency for Research on Cancer. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man. Some Anti-thyroid and Related Substances, Nitrofurans and Industrial Chemicals. Vol. 7. 326 pp. Lyon, France: IARC, 1974.

IARC. International Agency for Research on Cancer. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Chemicals, Industrial Processes and Industries Associated with Cancer in Humans. Supplement 4. 292 pp. Lyon, France: IARC, 1982.

IARC. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Overall Evaluations of Carcinogenicity. Supplement 7. 440 pp. Lyon, France: IARC, 1987.

IARC. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Some Thyrotropic Agents. Vol. 79. 763 pp. Lyon, France: IARC, 2001.

NIOSH. National Institute for Occupational Safety and Health. National Occupational Hazard Survey (1972-74). Cincinnati, OH: Department of Health, Education, and Welfare, 1976.

NIOSH. National Institute for Occupational Safety and Health. National Occupational Exposure Survey (1981-83). Cincinnati, OH: Department of Health and Human Services, 1984.

NTP. National Toxicology Program. Chemical Repository, 6-N-Propyl-2-Thiouracil. Last updated August 13, 2001. (http://ntp-server.niehs.nih.gov and search 51-52-5).

TSCA. Toxic Substances Control Act, Chemical Substance Inventory, 1979: public record.